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5Introduction
Hepatic resection is the only curative treatment for many
liver tumours. Relatively high intraoperative blood loss his-
torically has been a common complication of hepatic resec-
tion, frequently resulting in the need for transfusion of
blood [1–3]. In addition, major blood loss and transfusion of
HB are associated with postoperative complications and
death [4–7]. Numerous strategies to reduce blood loss dur-
ing hepatic resections have been reported in the literature.
However, little is known about the relative importance of
the various interventions or the impact of their combined
implementation on a surgeon’s practice. Recognising the
need for minimising blood loss in hepatic resections, we
introduced a number of strategies aimed to reduce haemor-
rhage. This was designated the Minimal Blood Loss (MBL)
programme for liver resections and was implemented in
1991. The MBL strategies include preoperative autologous
blood (AB) donation and several intraoperative manoeu-
vres, including the administration of aprotinin, low CVP
anaesthesia (£ 6 mmHG), temporary hepatic vascular
inflow occlusion (Pringle manoeuvre), ultrasonic dissection
(Cavitron Ultrasonic Surgical Aspirator, Valleylab, Pfizer
Co.), and the use of the Cell Saver to recycle autologous
blood intraoperatively.
Aprotinin, a serine protease inhibitor, minimises hepa-
tocellular injury and reduces blood loss. This drug, which is
administered intravenously, reduces blood loss through the
inhibition of fibrinolytic activity and preservation of the
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Background
Substantial blood loss and the requirement for blood
transfusion remain major considerations for hepatic sur-
geons. We analysed the impact of a systematic protocol
aimed at reducing intraoperative blood loss and homo-
logous blood (HB) transfusion associated with hepatic
resection.
Methods
Prospective clinical data were collected from 151 elective
liver resections performed during the period between
1980 and 1999. Further data directly related to blood loss
and anaesthesia were retrospectively collected from the
anaesthetic intra-operative record. Strategies implemented
in 1991 included preoperative autologous blood donation,
low central venous pressure anaesthesia, aprotinin admin-
istration, ultrasonic dissection, hepatic vascular inflow
occlusion and a Cell Saver. Blood loss and transfusion
requirements were studied before and after the imple-
mentation of these strategies.
Results
There was no difference in the patient demographics,
indications for operation or the scope of resections in the
two time periods evaluated.Blood-savin g strategies resulted
in decreased estimated blood loss (4500 mL vs. 1000 mL
p < 0.001). In addition, the number of patients requiring
transfusion decreased (91.8% vs. 25.5% respectively, p <
0.001) and the mean number of units of HB transfusion was
lower (13.7 vs. 2.3, p < 0.001).Morbidity and mortality were
also decreased (57.1% vs. 25.5%, p < 0.001 and 10.2% and
4.9% p < 0.001, respectively). No complications directly
referrable to low CVP anesthesia were identified .
Conclusion
Systematic implementation of strategies designed to con-
trol blood loss are effective and may reduce morbidity and
mortality associated with hepatic resections.
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action of platelet binding [8–9]. Studies have shown that
aprotinin is effective in reducing blood loss in hepatic
resection and transplantation [10–12]. We, and others,
have shown that low CVP anaesthesia significantly reduces
blood loss during parenchymal transection by keeping the
hepatic venous pressure low [13–15]. In a recent series,
Melendez and colleagues showed that low CVP anaesthesia
was associated with decreased blood loss and death. The
Pringle manoeuvre occludes liver vascular inflow during
the transection phase and has been reported to reduce
blood loss [16–17]. The Cavitron uses high frequency ultra-
sound waves to dissect liver parenchyma, leaving blood
vessels and bile ducts intact so that they can be accurately
ligated before transect. Ultrasonic dissection is widely used
in hepatic, neurological and urological surgery and repre-
sents an advance over the standard crush clamp approach
to hepatic parenchymal transection [18–21]. The Cell
Saver retrieves the patient’s own blood loss intraopera-
tively, allowing it to be transfused into the patient.
The primary objective of this study is to evaluate the
effectiveness of the MBL strategy in reducing blood loss
and to assess the relative importance of the various compo-
nents of the MBL strategy. A secondary objective was to
study the impact of the autologous blood donation
programme on homologous blood transfusion requirements.
Materials and methods
All hepatic resections in this series were performed by a
single surgeon (SSH). Clinicopathological data on all
patients were captured in a prospectively collected data-
base, and a chart review was conducted on all 151 cases to
ensure completeness and accuracy. Two groups of patients
are described: the pre-MBL group (1980–90; n = 49) and
the MBL group (1991–99; n = 102). In the era before the
institution of the MBL policy, liver resections were done
without the regular implementation of these strategies.
Importantly, CVP was often maintained at a high level in
anticipation of blood loss, and parenchymal transection
was performed with a finger fracture technique. In the MBL
era, CVP was routinely maintained £ 6.0 mmHg by restrict-
ing the patient’s intravenous fluids during parenchymal
transection. Neither positive end expiratory pressure
(PEEP) nor intermittent positive pressure (IPP) ventilation
was used, so that ventilation did not have an appreciable
impact on CVP measurement. Aprotinin administration in
the MBL era involved a 2 million unit bolus at the start of
hepatic transection, followed by a 0.5 million units every
hour, up to 4–5 million units in total. Transfusion of AB
and HB includes all units of blood transfused intraopera-
tively and postoperatively until discharge.
Statistical Analysis
We examined estimated blood loss (EBL) in the group with
no MBL strategy and the group with the MBL, using a uni-
variate analysis. MBL strategies (Pringle, Cavitron, CVP,
aprotinin, Cell Saver) were included in a regression model,
along with potential confounding factors including opera-
tive time (ORT), number of liver lesions, size of largest
lesion, number of segments resected, age, sex and preoper-
ative liver function. The primary end point was EBL.
Similarly, stepwise multiple linear regression was used to
determine predictors of HB transfusion requirements. The
impact of the MBL strategy and the AB program on HB
transfusion requirements was determined.
Results
Patient demographic and clinical data are presented in
Table 1. Resections were carried out for a variety of indica-
tions, including primary and secondary hepatic malignan-
cies and benign hepatic lesions. There were no significant
differences between the groups with respect to the com-
plexity of resections. This fact is demonstrated by the simi-
larity in operating time, type of resection and the number
of segments resected. 
By contrast, there is a marked difference in all parame-
ters pertaining to blood loss and transfusion between the
two periods (Table 2). Univariate analysis indicated that
each of the factors of the MBL was associated with reduced
blood loss. There was a significantly lower mean CVP dur-
ing the transection phase in the MBL group compared to
the pre-MBL group (6.4 versus 11.9, p < 0.001). No
detectable changes in CVP were observed with normal
ventilation. Patients in the MBL group had significantly
greater use of the Cavitron, aprotinin, and Cell Saver than
patients in the pre-MBL group (p < 0.001). Multiple linear
regression modelling indicated that low CVP anaesthesia
and aprotinin were the only significant independent pre-
dictors of blood loss. Not surprisingly, duration of operation
(which is a marker of case complexity) also remained a
significant predictor of blood loss (Table 3).
In addition, the overall rate of HB transfusion require-
ments and the total number of units transfused were signif-
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icantly lower in the MBL period. The mean amount of HB
transfused for the MBL group was 2.3 ± 0.4 units compared
to 13.7 ± 1.8 units in the pre-MBL (p < 0.001). The per-
centage of patients receiving one or more units of HB
decreased from 96.9% to 29.5% for major resections
(p < 0.001) and from 82.3% to 19.5% for minor resections
(p < 0.001). After the initiation of the AB donation pro-
gramme mean HB transfusions for major resections
decreased from 11.1 ± 1.6 units to 1.5 ± 1.1 units
(p < 0.001) and for minor resections from 3.6 ± 1.1 units to
0 units (p = 0.027).
Although there were no differences in the rates of sepsis
and re-operation for postoperative haemorrhage between
the two groups, overall morbidity was significantly lower in
Table 1. Patient demographics and clinical data
Total # of patients (%) Pre-MBL MBL p-value
Number of patients 151(100) 49 102
Mean age (years) 60.4 59 61 0.454
Sex
Male 78(51.7) 24(49.0) 54(52.9) 0.651
Female 73(48.3) 25(51.0) 48(47.1) 0.651
Procedure
Major resection 93(61.6) 32(65.3) 61(59.8) 0.518
Minor resection 58(38.4) 17(34.7) 41(40.2) 0.518
Indications
Hepatoma 13(8.6) 4(8.2) 9(8.8) 0.880
Metastatic tumour 110(72.9) 34(69.4) 76(74.5) 0.622
Benign tumour 28(18.5) 11(22.4) 17(16.7) 0.504
Table 2. Comparison of MBL and Pre-MBL Grops
Variable Pre-MBL (n = 49) MBL (n = 102) p-value
Duration of operation 353 min 363 min 0.727
Type of resection
Major* 32(65.3%) 61(59.8%) 0.518
Minor 17(34.7%) 41(40.2%) 0.518
Number of segment resected 3.5 3.4 0.631
Mean estimated blood loss 8018 ± 260 mL 1809 ± 110 mL < 0.001
Median estimated blood loss 4500 mL 1000 mL
Mean CVP 11.9 ± 1.2 mmHG 6.4 ± 0.3 mmHG < 0.001
Cavitron use 23(47%) 97(95%) < 0.001
Aprotinin use 0(0%) 91(89%) < 0.001
Cell Saver use 0(0%) 21(20.6%) < 0.001
Mean # of units of HB transfused 13.7 ± 1.8 2.3 ± 0.4 < 0.001
Mean # of units of AB transfused 0 0.72 ± 0.2 < 0.001
Mean total # of units transfused 13.7 ± 1.8 3.0 ± 0.4 < 0.001
Patients receiving 1 or more units of HB
Major resection 31(96.9%) 18(29.5%) < 0.001
Minor resection 14(82.3%) 8(19.5%) < 0.001
Total 45(91.8%) 18(25.5) < 0.001
Morbidity
Haemorrhage† 4(8.2%) 3(2.9%) 0.159
Bile leak 6(12.2%) 12(11.8%) 0.949
Sepsis 14(28.6%) 9(8.8%) < 0.001
Other 18(36.7%) 15(14.7%) 0.002
Overall morbidity‡ 28(57.1%) 26(25.5%) < 0.001
Mortality (pen-operative) 5(10.2%) 5(4.9%) < 0.001
*Major resection is defined as 3 or more segments resected.
†Requiring re-operation for haemorrhage.
‡Patients having 1 or more postoperative complications (bleeding, bile leak, sepsis, other).
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the MBL than the pre-MBL group, 25.5% versus 57.1%,
(p < 0.001). Moreover, the mortality rate was 4.9% in
the MBL group compared to 10.2% in the pre-MBL
group (p < 0.001). No patients were identified with serious
significant renal dysfunction, myocardial ischemia or air
emboli in the era of low CVP anaesthesia.
A subgroup analysis of blood loss and transfusion
parameters was conducted for the 20 consecutive patients
just before, and the 20 patients following, institution of
MBL. This analysis was done to control for surgeon’s
increasing experience as a factor affecting blood loss with
liver resections. Table 4 shows that the first 20 cases after
1991 had a significantly lower EBL than the 20 cases before
1991, but there was no significant difference in duration or
the number of segments resected.
Discussion
This study shows that the systematic implementation of
strategies aimed to minimise haemorrhage has reduced the
estimated blood loss (EBL) in hepatic resections since
1991. Although each factor probably makes an independ-
ent contribution to lessen blood loss, it is likely that the
combination of these strategies is most important. Like
others, we found that aprotinin was useful in reducing
blood loss associated with parenchymal transection [10,
21]. Perhaps more importantly, assiduous control of CVP
during the parenchymal transection phase of hepatectomy
is a critical determinant of reduced blood loss from hepatic
venous branches [11–13, 15]. The maintenance of low
CVP often requires a special effort on the part of the
anaesthetist, in coordination with the surgeon. Like oth-
ers, we did not find any complications directly referrable
to low CVP anaesthesia [15]. Importantly, the benefits
accrued from low CVP anaesthesia should be balanced
against the potential risk of diminished cardiac output
that may occasionally accompany efforts to reduce CVP.
At the discretion of the anaesthetist, it was sometimes
necessary to insert a Swan-Ganz catheter or to increase
CVP to optimise cardiac output. CVP readings are
dependent on the positioning of the patient and the level
at which the reading is ‘zeroed’. Close attention to such
details is important to be certain the absolute CVP read-
ing is relevant. Although not as important in the
statistical modelling of EBL, it is likely that the addition
of the Pringle manoeuvre, Cell Saver and Cavitron play
some role in the success of the MBL strategy.
The duration of operation was a significant predictor of
blood loss. Factors that may increase operative duration
such as variations in liver anatomy, underlying coagu-
lopathies and extent of resection, may also increase blood
loss. Therefore, duration served as a surrogate marker for
these factors. It is possible that surgeon experience may
affect blood loss, but in our subgroup analysis of 20 cases
before and after 1991, there was still a significantly lower
amount of blood loss with the implementation of the MBL
strategy, suggesting that these strategies caused a marked
improvement in blood loss.
Not surprisingly, the institution of MBL was associated
with decreased transfusion requirements as a result of
decreased blood loss. In addition, the implementation of
the AB programme resulted in a further decrease in the
need for HB transfusion. This finding is especially relevant
in an era in which the risk and cost of transfusion are of
increasing importance [22]. Perhaps most importantly, the
institution of MBL is associated with a decrease in morbid-
ity and mortality rates in patients undergoing resection.
Although this may in part be due to increasing surgeon
experience, it seems likely that reduced blood loss
contributes to these improved outcomes.
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Table 3. Multiple linear regression model of predictor of
estimated blood loss (EBL)
Predictors Univariate Multivariate 
p-value p-value
Duration of operation 0.727 < 0.001
Mean CVP < 0.001 0.044
Aprotinin < 0.001 < 0.001
Pringle manoeuvre < 0.001 0.412
Cell Saver 0.001 0.669
Cavitron < 0.001 0.819
Number of liver lesions 0.795 0.710
Size of largest lesion 0.766 0.651
Number of segments resected 0.631 0.753
Age 0.454 0.502
Sex 0.651 0.294
Pre-operative liver function 0.638 0.145
Table 4. Comparison of median estimated blood loss (EBL) in
20 cases prior to 1991 and 20 cases after 1991
20 cases 20 cases
prior to 1991 after 1991 p-value
Median EBL (mL) 4100 1650 < 0.001
ORT (min) 359 364 0.930
Number of segment 
resected 2.9 2.8 0.850
ORT = operating room time
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The results of this study suggest that liver resections
done with careful attention to strategies aiming to reduce
blood loss are effective in reducing intraoperative blood
loss and HB transfusion requirements. These results under-
score the importance of developing a programmatic
approach to liver resection that includes cooperation and
coordination between anaesthetist and surgeon in both the
preoperative period (AB donation) and intraoperative
period (aprotinin administration and maintenance of low
CVP). Such an approach can lead to dramatic reduction in
blood loss and thus obviate one of the major causes of
complications and death in hepatic resection.
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